Ashwagandha

Withania somnifera is in Solanaceae. The nightshade family. Its cousins, by the same taxonomic distance that separates wolves from foxes, are:

the tomato on your counter; the potato in your pantry; the eggplant, the chili, the bell pepper; tobacco; petunias in the planter; datura, the deliriant of New World shamans; deadly nightshade (Atropa belladonna), the lethal atropine-bearer; mandrake, the screaming root of European witchcraft; henbane, the herb of Hamlet’s father’s murderer.

The supplement aisle’s calmest-selling herb sits one taxonomic step from the most psychoactively dangerous plants on Earth. You eat the family every day in lasagna. You take the family before bed in a 600-milligram capsule. You almost died of the family in 1567 if you ate a wild berry that looked like a small cherry.

Open a 300-milligram KSM-66 capsule. Inside is milled root, some carbohydrate, and roughly fifteen milligrams of a class of molecules called withanolides — C₂₈ steroidal lactones that share a four-ring backbone with cholesterol, cortisol, and testosterone. The most-studied member, withaferin A, has the formula C₂₈H₃₈O₆ and carries an electrophilic α,β-unsaturated ketone on one ring and an epoxide on another. Both groups react covalently with cysteine residues on proteins. The active fraction of every ashwagandha capsule is, in chemical terms, a small electrophile dressed up as a steroid.

It was first isolated in 1965 at the Daniel Sieff Research Institute of the Weizmann Institute of Science, in Rehovot, Israel, by David Lavie, Erwin Glotter, and Yehuda Shvo. Their structural paper appeared in the Journal of the Chemical Society. The Sanskrit horse-smell got its first molecular formula in an Israeli organic-chemistry lab, eight years before the Yom Kippur War.

The man behind the word had spent World War II assigned to studying military psychotropics — amphetamines, cocaine, drugs that wrung performance from soldiers at a cost. After the war, Lazarev asked whether there was a class of substance that could produce the resistance of a stressed organism without the exhaustion of one. He took the framing from Hans Selye’s 1936 paper on the general adaptation syndrome. The molecule that gave Lazarev the term was dibazol, a French-developed arterial dilator that produced a generalized state of resistance in animals.

The concept passed to Lazarev’s student, Israel Brekhman, who set up at the Far East Branch of the Soviet Academy of Sciences in Vladivostok and spent the next two decades testing Far Eastern plants against the framework. His flagships were Eleutherococcus senticosus (Siberian ginseng) and Schisandra chinensis. They were standard supplies on Soyuz missions and Soviet Olympic teams. Through the Cold War, “adaptogen” was a state-sponsored category in Soviet pharmacology.

Ashwagandha was not on Brekhman’s list. The Sanskrit herb was folded into the framework in the 1970s and 80s — first by Indian researchers reading the Russian literature in translation, then by Western marketers needing a pharmacological label more legible than rasayana. The 3,000-year-old Vedic root now wears a Stalin-era Russian category on its bottle.

The verse is from the Bhavaprakasha Nighantu — a 16th-century materia medica containing 10,268 verses and roughly 500 plant entries. The Sanskrit category for this kind of substance is vajikarana — from vaji, “horse” — drugs that restore a man to the strength of a stallion. Charaka, Sushruta, Bhavaprakasha: three texts across fifteen hundred years, in a tradition with no shortage of vocabulary, all reach for the same animal. The metaphor was not decorative. It was structural.

In 2015, in a resistance-training trial of 57 untrained young men in India, the ashwagandha group added 46 kilograms to their bench-press one-rep-max over eight weeks. The placebo group added 26. Testosterone rose roughly 22% in the treatment arm versus 6% in placebo. A separate trial the same year reported sperm counts in oligospermic men going from 9.6 million per milliliter to 25.6 million per milliliter over 90 days.

The bench-press numbers did not validate the metaphor. They retroactively grounded it. Whatever the 1st-century-BCE Ayurvedic physicians were seeing in their patients was the same kind of effect that a 2015 trial in Pune could measure with a barbell.

In 2012, K. Chandrasekhar and colleagues published a randomized, double-blind, placebo-controlled trial of ashwagandha in 64 chronically stressed Indian adults. Sixty days. Three hundred milligrams of KSM-66 extract twice a day. The headline number — a 27.9% reduction in serum cortisol in the treatment arm versus 14% in placebo — became the most-cited piece of ashwagandha evidence in the Western popular press. The 300mg-BID dose became the de facto retail standard for the next decade.

The bush is a scrubby evergreen, half a meter tall, with soft pubescent leaves and small five-petalled greenish-yellow flowers nobody photographs. The fruit is an orange-red pea inside a papery lantern, indistinguishable from a Cape gooseberry. The root smells like a horse.

Twenty centuries of Sanskrit physicians called it rasayana. Two centuries of European herbalists called it somnifera. Eight decades of Soviet pharmacologists called it adaptogen. Six decades of Israeli, Indian, and American chemists called it withaferin A and went looking for cancer applications. The bottle on the nightstand says all four things at once and none of them. The plant has not changed in three thousand years. The frames we have used to know it have multiplied without resolving — and the next century’s frame, whatever it turns out to be, is already implicit in some Phase II trial or some Ayurvedic verse nobody has read in eight hundred years.